Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:Q17RS7 (
Gen
)
130,125
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
This article reviews all the prospective, double-blind controlled studies that have evaluated the prediction of response to imipramine hydrochloride and amitriptyline hydrochloride in depressed patients. Despite widely divergent methodologies, an attempt is made to extract clinically useful conclusions from these data. Critiques of each study and the criteria used in their evaluation are presented, with suggestions for future research included. The predictors of positive response to imipramine and amitriptyline are as follows: upper socioeconomic class, insidious onset,
anorexia
, weight loss, middle and late insomnia, and psychomotor disturbance. The predictors of poor response are the following: neurotic, hypochondriacal, and hysterical traits, multiple prior episodes, and delusions. Pretreatment urinary 3-methoxy-4-hydroxyphenylglycol (MHPG) levels may some day be useful in predicting to which of these two tricyclic antidepressants a patient will respond.
Arch
Gen
Psychiatry 1976 Dec
PMID:Prediction of tricyclic antidepressant response: a critical review. 79 64
1. Five oxazolidines were synthesized by reaction of (-) ephedrine with aliphatic aldehydes. The aldehydes used were formaldehyde, propionaldehyde, butyraldehyde, isobutyraldehyde and trimethylacetaldehye. 2. These five oxazolidines were tested in rats for ephedrine-like pharmacological activity using the hyperthermia and
anorexia
models. 3. All five oxazolidines caused significant elevation of body temperature in the hyperthermia model. The oxazolidine synthesized from (-) ephedrine and butyraldehyde caused greatest hyperthermia. 4. Four oxazolidines caused significant anorectic responses. The oxazolidine synthesized from (-) ephedrine and isobutyraldehyde caused greatest
anorexia
. 5. A possible tolerance to the anorectic effects of some of the compounds was observed.
Gen
Pharmacol 1992 Jul
PMID:Effects of oxazolidines derived from (-) ephedrine in the rat. 139 80
1. The anorectic effect of dopamine agonists and antagonists were studied in rats. 2. Dopamine agonists bromocriptine, quinpirole or SKF 38393 treatment induced, a dose-dependent
anorexia
in rats. 3.
Anorectic
effect of bromocriptine was decreased in animals pretreated with pimozide (D-2 antagonist), but not by sulpiride (D-2 antagonist) or SCH 23390 (D-1 antagonist) pretreatment. 4.
Anorexia
induced by quinpirole was decreased by sulpiride or pimozide, but not by SCH 23390 administration. 5. While sulpiride and SCH 23390 failed to antagonize the anorectic response of SKF 38393, methergoline (5-HT antagonist) decreased
anorexia
induced by the drug. 6. A combination of quinpirole with SKF 38393 did not elicit potentiated anorectic response. 7. Decrease in food intake induced by bromocriptine, quinpirole or SKF 38393 was potentiated in reserpinized animals, although single administration of reserpine also induced a marked decrease in feeding. 8. Single administration of sulpiride, pimozide or methergoline did not change the feeding behaviour of rats, but SCH 23390 induced
anorexia
. 9. It is concluded that D-2 activation may induce inhibition of feeding and
anorexia
induced by SKF 38393 may be mediated through serotonergic mechanism(s).
Gen
Pharmacol 1991
PMID:Evaluation of dopamine receptor involvement in rat feeding behaviour. 168 90
The related central nervous system peptides neuropeptide Y and peptide YY have been found to be among the most potent endogenous stimulants of feeding behavior. We measured these neuropeptides in cerebrospinal fluid to determine whether they contributed to the pathophysiologic characteristics of
anorexia
and bulimia nervosa. Cerebrospinal fluid neuropeptide Y concentrations were significantly elevated in underweight anorectic patients and in many of the anorectic patients studied at intervals after weight restoration. These levels normalized in long-term weight-restored anorectic patients who had a return of normal menstrual cycles. Increased neuropeptide Y activity may contribute to several characteristic disturbances in
anorexia
, including menstrual dysregulation. Cerebrospinal fluid peptide YY concentrations were significantly elevated in normal-weight bulimic patients abstinent from pathological eating behavior for a month compared with themselves when actively bingeing and vomiting or compared with healthy volunteers. Increased peptide YY activity may contribute to a drive to overfeed in normal-weight bulimic patients.
Arch
Gen
Psychiatry 1990 Jun
PMID:Altered cerebrospinal fluid neuropeptide Y and peptide YY immunoreactivity in anorexia and bulimia nervosa. 235 Feb 7
Eighteen untreated cancer patients and ten sex- and age-matched healthy volunteers were studied. In all patients eating behavior was investigated by means of a specific questionnaire from which the presence of
anorexia
and
anorexia
-related symptoms was assessed. To investigate the role of tryptophan in cancer
anorexia
, fasting plasma and CSF levels of tryptophan and other neutral amino acids were assayed in patients and controls. Cancer patients showed abnormally high plasma free tryptophan levels. In case of patients with cancer
anorexia
a significant rise of the ratio in plasma between free and tryptophan/large neutral amino acids, competing with tryptophan for its brain entry, was observed. This increase was correlated to a consistent rise of CSF tryptophan levels suggesting a specific role of the serotoninergic system in the pathogenesis of cancer
anorexia
.
J Neural Transm
Gen
Sect 1990
PMID:Plasma and CSF tryptophan in cancer anorexia. 239 86
1. Baclofen given intraperitoneally (i.p.) to rats caused a dose-dependent decrease in food intake. 2. Bicuculline or picrotoxin (GABAA-antagonist) and methergoline (5-HT antagonist) decreased the anorectic effect of baclofen. 3. Pimozide (dopamine receptor blocker), phenoxybenzamine and propranolol (alpha and beta adrenergic blockers) did not diminish the baclofen effect, but even increased the
anorexia
induced by the drug. 4. It can be postulated that, at least partially, GABAA receptor mechanism, GABA-5HT receptor complex and/or 5-HT mechanism may be involved in baclofen induced
anorexia
.
Gen
Pharmacol 1989
PMID:Food intake suppressant effect of baclofen in rats. 260 37
Fencamfamine (1.0-10.0 mg/kg, i.p. single dose) reduced the food intake in a dose-effect relationship. The dose needed for the 50% inhibition of food intake (ID50) was 7.3 mg/kg. Fencamfamine-induced
anorexia
in rats (5.0 and 10.0 mg/kg) was followed by hyperactivity, stereotypy or both. Pretreatment with haloperidol antagonized the anoretic effect induced by fencamfamine. These findings suggest that the activation of central dopaminergic systems involved in feeding regulation may be responsible for the anoretic effect of fencamfamine and that this effect is associated with other central stimulant effects.
Gen
Pharmacol 1987
PMID:Reduction of food intake by fencamfamine in rats. 288 32
The literature describing nondyskinetic antipsychotic withdrawal symptoms is reviewed. The withdrawal of antipsychotic agents can result in nausea, emesis,
anorexia
, diarrhea, rhinorrhea, diaphoresis, myalgias, paresthesias, anxiety, agitation, restlessness, and insomnia. Psychotic relapse is often presaged by increased anxiety, agitation, restlessness, and insomnia. However, the temporal relationship of these prodromal symptoms to reduction in the dosage or discontinuation of neuroleptics distinguishes them from the effects of abrupt withdrawal.
Gen
Hosp Psychiatry 1988 Nov
PMID:Antipsychotic withdrawal phenomena in the medical-surgical setting. 290 18
1. Bupropion (12.5-75 mg kg-1) was given intraperitoneally to rats and was found to decrease the food consumption of the animals dose-dependently. While phenoxybenzamine, propranolol and methergoline failed to antagonize the anorectic effect of the drug; pimozide a dopamine receptor blocker decreased
anorexia
induced by bupropion. 2. Bupropion (12.5-50 mg kg-1) also caused a marked increase in locomotor activity of the rats. The increase in locomotion produced by bupropion was completely antagonized by pretreatment of the animals with pimozide and reserpine plus a-methyl-p-tyrosine, but not by pretreatment with phenoxybenzamine, propranolol or methergoline. 3. Taking into considerations the evidences of dopaminergic properties of bupropion shown by the others, it could be suggested that the
anorexia
and hyperactivity produced by bupropion may be induced through the indirect dopaminergic mechanism.
Gen
Pharmacol 1988
PMID:Anorectic and behavioural effects of bupropion. 312 69
1. Different doses of ephedrine (3.1-50 mg kg-1) were given intraperitoneally to rats and found to decrease food intake dose-dependently. 2. The anorectic effect of ephedrine was decreased by animal pretreatment with pimozide, but phenoxybenzamine, propranolol and methergoline did not decrease the response. 3. The results show that the
anorexia
produced by ephedrine may be due to indirect dopaminergic mechanism of the drug.
Gen
Pharmacol 1987
PMID:Anorectic effect of ephedrine. 365 77
1
2
3
4
5
Next >>